Alfacell (ACEL) Announces Paper in Cell Cycle Reports ONCONASE(R) Targets siRNA

October 9, 2008 8:45 AM EDT

Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE targets small interfering RNA, likely within the RNA-induced silencing complex of the RNA interference mechanism.

The paper is the result of research conducted by collaborators at the Brander Cancer Research Institute and Department of Pathology at New York Medical College and Alfacell. The study demonstrated that silencing the glyceraldehyde 3-phosphate dehydrogenase gene (an abundant and ubiquitously expressed housekeeping gene) in human lung adenocarcinoma A549 cells by siRNA was effectively prevented by ONCONASE. While transfection of cells with GAPDH siRNA reduced expression of this protein by nearly 70 percent, the expression was restored in the cells exposed to ONCONASE for 48 or 72 hours. The data thus provide evidence that one of the targets of ONCONASE is siRNA.

Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?